Physician profile
Howard Crisp
NPI 1760608442
$12,815.98
in general payments reported to CMS, 2019-2025
38 companies · $3,336 in 2025
The $3,336 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $885 · 2021: $1,322 · 2022: $1,866 · 2023: $1,657 · 2024: $2,745 · 2025: $3,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,491 · Education: $207 · Consulting Fee: $39.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,491.26 |
| Education | $206.76 |
| Consulting Fee | $39.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,578.07 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,636.77 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,377.53 | 2019-2025 | Dupixent |
| Genzyme Corporation | $990.69 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $788.49 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Pfizer INC. | $770.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $526.48 | 2019-2025 | |
| Alk-Abello, INC | $477.85 | 2019-2024 | Odactra, Ragwitek, Grastek |
| Amgen INC. | $364.48 | 2023-2025 | Tezspire, Tavneos |
| Csl Behring | $339.35 | 2021-2025 | Hizentra, Haegarda, Privigen |
| Grifols USA, LLC | $327.32 | 2019-2025 | Xembify |
| Leo Pharma INC. | $300.94 | 2022-2025 | Adbry |
| Blueprint Medicines Corporation | $290.38 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $283.68 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $268.59 | 2025 | Neffy |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $220.76 | 2020-2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $138.14 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.41 | 2020-2021 | |
| Insmed, INC. | $89.98 | 2025 | Brinsupri, Arikayce |
| Biocryst US Sales Co., LLC | $89.85 | 2024-2025 | Orladeyo |
| Optinose US, INC. | $89.52 | 2019-2021 | |
| Pharming Healthcare, INC. | $74.85 | 2022-2025 | Ruconest |
| Sanofi-Aventis U.S. LLC | $74.05 | 2020-2021 | |
| Incyte Corporation | $73.32 | 2022-2025 | Opzelura |
| Hospira, INC. | $64.96 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $59.28 | 2024-2025 | Ryaltris |
| Adma Biomanufacturing LLC | $57.35 | 2021-2024 | |
| Ionis Pharmaceuticals, INC. | $49.96 | 2025 | Dawnzera |
| Lilly USA, LLC | $49.15 | 2024-2025 | Taltz, Ebglyss |
| Octapharma USA, INC. | $46.27 | 2022-2023 | Cutaquig |
| Shire North American Group INC | $41.86 | 2019 | |
| Merck Sharp & Dohme LLC | $38.76 | 2021-2023 | |
| Organon LLC | $30.68 | 2025 | |
| Greer Laboratories, INC. | $25.85 | 2024 | Palforzia |
| Abbvie INC. | $24.81 | 2023 | Rinvoq |
| Azurity Pharmaceuticals, INC. | $23.82 | 2025 | Alvesco |
| Covis Pharma Gmbh | $22.64 | 2021 | |
| Galderma Laboratories, L.P. | $18.52 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Crisp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.